NAC (N-acetyl cysteine) has one of the longest research histories of any supplement when it comes to lung health. It has been used medically for airway conditions since the 1960s, and the evidence base — while not without nuance — is considerably more developed than for most supplements marketed with lung health claims.
This article covers what NAC actually does in the lungs, where the evidence is strong, and what realistic expectations look like.
How NAC Affects the Lungs
NAC works in the respiratory system through two distinct but complementary mechanisms.
Mucus thinning (mucolytic action)
Mucus is held together by disulphide bonds between mucin proteins. NAC contains a free thiol (sulphydryl) group that breaks these bonds directly, reducing the viscosity of mucus and making it easier to clear from the airways. This is a chemical action — it does not depend on glutathione or antioxidant activity.
This mechanism is well established and is the reason NAC has been used as a mucolytic agent in respiratory medicine for decades, both as an inhaled treatment (nebulised NAC) and orally. It is particularly relevant in conditions characterised by thick, tenacious mucus secretions.
Antioxidant support via glutathione
The lungs are continuously exposed to oxidants from inhaled air, pollution, cigarette smoke, and pathogens. The respiratory epithelium — the cells lining the airways — is highly dependent on glutathione for protection against this oxidative challenge.
Research has shown that the airway lining fluid contains high concentrations of glutathione, significantly higher than in blood plasma. This reflects the lung’s particular need for antioxidant defence. By supplying cysteine for glutathione synthesis, NAC supports this defence layer. For a detailed look at this mechanism, see our article on how NAC boosts glutathione. This mechanism is relevant across a wide range of respiratory conditions where oxidative stress is elevated.
COPD: The Strongest Evidence
COPD (chronic obstructive pulmonary disease) is the condition with the most substantial research on NAC. Oxidative stress is a key driver of COPD progression, and glutathione depletion is consistently documented in COPD patients — both in blood and in lung tissue.
The landmark study in this area is the BRONCUS trial — a large, randomised, placebo-controlled trial published in The Lancet that assessed whether NAC (600mg per day) could reduce exacerbations and slow lung function decline in COPD. The primary endpoint (exacerbation rate) was not met in the overall group. However, a pre-specified subgroup analysis found that patients not on inhaled corticosteroids had significantly fewer exacerbations with NAC — suggesting the effect may be masked when the inflammatory pathway is already being addressed pharmacologically.
A later meta-analysis published in CHEST pooled data from multiple NAC trials in COPD and found a significant reduction in exacerbation frequency with NAC supplementation at doses of 600mg or higher. The reviewers concluded that the evidence supported NAC’s use as an add-on therapy in COPD, particularly at higher doses than used in BRONCUS.
The PANTHEON trial, published in The Lancet Respiratory Medicine, randomised 1,006 Chinese COPD patients to 1,200mg NAC per day or placebo over one year. NAC reduced exacerbations by 22% (RR 0.78, 95% CI 0.67–0.90, p=0.001) — and unlike the BRONCUS result, this benefit held regardless of inhaled corticosteroid use, strengthening the case for higher doses.
Chronic Bronchitis
Chronic bronchitis — persistent mucus production and cough — is one of the conditions where NAC’s mucolytic mechanism is most directly relevant. Multiple studies and meta-analyses have found that oral NAC reduces symptoms of chronic bronchitis, including cough frequency and mucus volume.
A Cochrane review of oral mucolytics in chronic bronchitis found that treatment was associated with a significant reduction in exacerbations and days of illness per year compared with placebo. NAC was the most studied agent in the trials included.
Acute Respiratory Infections
NAC has been investigated for its potential to support the immune response during acute respiratory illness, primarily through its antioxidant and anti-inflammatory effects.
A notable Italian trial published in the European Respiratory Journal randomised elderly patients to 600mg NAC twice daily or placebo over the winter influenza season. Those taking NAC were significantly less likely to develop influenza-like symptoms, and those who did become infected reported milder and shorter illness. The researchers attributed this to NAC’s ability to modulate the immune response and reduce oxidative stress during infection.
This was a single trial in an older population and should not be over-interpreted as establishing NAC as a flu preventative. However, it points to a plausible and mechanistically coherent benefit in the context of acute respiratory infection.
Idiopathic Pulmonary Fibrosis (IPF)
IPF is a progressive lung condition characterised by fibrosis of the lung tissue. Oxidative stress and glutathione depletion have been identified as key factors in its pathogenesis — research indicates that IPF patients have approximately four times lower glutathione levels in lung tissue compared to healthy individuals, reflecting the severity of redox imbalance in the condition.
High-dose NAC (1,800mg per day) was studied as a potential treatment in the PANTHER-IPF trial, published in the New England Journal of Medicine. The trial arm testing NAC in combination with prednisone and azathioprine was stopped early due to harm in the combination group (not attributable to NAC specifically). A later arm testing NAC alone versus placebo found no significant benefit. The IPF evidence is therefore not supportive, which is relevant context for claims about NAC and lung fibrosis.
NAC and Lung Repair
The term “lung repair” covers a range of situations — from recovery after an acute infection to the longer-term effects of cumulative damage from pollution exposure. NAC’s relevance here is primarily through its role in glutathione replenishment rather than any direct tissue-repair mechanism.
During and after acute respiratory illness, oxidative stress rises sharply in lung tissue. The inflammatory response that clears infection also generates free radicals that can cause secondary damage to the airway epithelium. Restoring glutathione availability after an infection or inflammatory episode may support the recovery process by reducing this oxidative burden — though direct clinical trials measuring lung recovery as a primary endpoint are limited.
A 2020 rapid review of NAC in acute viral respiratory infections found evidence of improved outcomes in hospitalised patients, including reduced mechanical ventilation duration and better recovery scores. Post-COVID observational data has similarly pointed to a plausible role for NAC in recovery from acute respiratory illness, where both oxidative stress and glutathione depletion are well-documented. The evidence here is preliminary but aligns with the same mechanisms established in COPD and chronic bronchitis research.
The same logic applies to cumulative oxidative damage from pollution or environmental exposure. NAC cannot reverse structural changes to lung tissue — fibrosis, for instance, is not reversible by supplementation. What it may support is a reduction in ongoing oxidative stress that, unchecked, would contribute to further decline. This rationale is mechanistically sound but not yet well-established in long-term human trials.
NAC is best understood as a support tool for the lung’s antioxidant defences during and after periods of oxidative challenge — not a lung regeneration supplement.
What About Healthy Adults?
Most of the clinical evidence for NAC in lung health involves people with established lung conditions. For healthy adults, the evidence is less developed.
The mucolytic effect is primarily relevant when excess or thickened mucus is a problem. For a healthy person with normal mucus production, this mechanism is not particularly applicable. The antioxidant mechanism is more broadly relevant — particularly for people with high-level occupational or environmental pollution exposure, or heavy exercise — but the evidence for meaningful clinical outcomes in healthy adults is limited.
For general lung health maintenance, optimising diet (adequate cysteine and selenium intake), avoiding smoking, and regular exercise have stronger evidence than supplementation in healthy adults. For information on potential side effects, see our glutathione side effects guide.
Dosage for Lung Support
The doses used in lung health research vary by condition:
- Mucolytic effect / chronic bronchitis: 600mg per day (most studied dose)
- COPD exacerbation prevention: 600–1,200mg per day; the PANTHEON trial found 22% fewer exacerbations at 1,200mg
- Acute infection support: 600mg twice daily in the Italian trial
For those using NAC for general lung support alongside other health goals, 600mg once daily is the most common practical recommendation and the dose at which most safety data has been generated. For a full discussion of NAC dosage and safety, see our NAC supplement guide.
Epsilon Life’s NAC+ provides 600mg N-acetyl cysteine per capsule — the dose used in the majority of clinical research on lung health. Vegan-certified and manufactured to GMP standards.
Frequently Asked Questions
What does NAC do for the lungs?
NAC acts on the lungs through two main mechanisms: it directly thins mucus by breaking the chemical bonds that hold mucin proteins together, and it supports the lung’s antioxidant defences by supplying cysteine for glutathione synthesis. Research shows that airway lining fluid contains far higher glutathione concentrations than blood plasma, reflecting the lung’s unusually high antioxidant requirements. These mechanisms underpin NAC’s use in conditions including COPD, chronic bronchitis, and acute respiratory infections.
Does NAC help with mucus?
Yes — NAC has a direct mucolytic (mucus-thinning) action. It contains a thiol group that breaks the disulphide bonds linking mucin proteins, reducing mucus viscosity. This is a chemical mechanism, independent of NAC’s antioxidant properties, and is the basis for its long-standing medical use as a mucolytic agent. It is most relevant in conditions where excess or thickened mucus is a problem.
Can NAC help with COPD?
Research suggests NAC may help reduce exacerbations in COPD, particularly at doses of 600–1,200mg per day. The PANTHEON trial found a 22% reduction in exacerbations at 1,200mg daily (RR 0.78, p=0.001), with benefit seen regardless of corticosteroid use. Earlier trials at 600mg showed mixed results. NAC should be considered an adjunct to — not a replacement for — prescribed COPD treatment.
Does NAC help with chest infections or flu?
One controlled trial found that older adults taking 600mg twice daily during winter had significantly fewer influenza-like illnesses than those on placebo, and milder symptoms when they did fall ill. This is a single study and should not be interpreted as establishing NAC as a flu treatment. However, the result is biologically plausible given NAC’s effects on oxidative stress and immune function.
Can NAC support lung recovery?
NAC may support lung recovery after infection or oxidative stress by replenishing glutathione, which is depleted during periods of acute inflammation. A 2020 review of NAC in acute viral respiratory infections found signals of improved recovery outcomes in hospitalised patients. There is no direct evidence that NAC repairs lung tissue structurally — its benefit in a recovery context is through reducing ongoing oxidative burden rather than regenerating damaged cells.
Can I use NAC for asthma?
The evidence for NAC in asthma specifically is limited and mixed. Some research suggests oxidative stress contributes to airway inflammation in asthma, which would make NAC’s antioxidant mechanism theoretically relevant. However, inhaled forms of glutathione have triggered bronchospasm in asthmatic individuals — oral NAC does not carry this risk, but anyone with asthma should discuss any new supplement with their GP or respiratory specialist before use.
How long does NAC take to work for respiratory symptoms?
In the context of mucus thinning, NAC’s effect can be relatively rapid — studies on nebulised NAC show effects within hours. For oral supplementation aimed at reducing exacerbation frequency in COPD, the benefits in clinical trials became apparent over months. For general glutathione support, the timeline is similar. NAC is not a rapid-acting remedy but a support tool that shows benefit over sustained use.
